SCHEMBL30735696

SCHEMBL30735696

FC(F)(F)c1ccc(C2CCNCC2)c2ccncc12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.50
SLC6A2 P23975 3/20 0.43
SLC6A4 P31645 3/20 0.43
HTR1A P08908 2/20 0.43
SLC6A3 Q01959 1/20 0.43
RPS6KA3 P51812 1/20 0.42
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
HTR6 P50406 2/20 0.36
NOTUM Q6P988 1/20 0.36
RBP4 P02753 1/20 0.36
APP P05067 1/20 0.36
PLAT P00750 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19297029 1.00 HTR2C (0.50) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL30735577 0.94 HTR2C (0.50) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL19297031 0.94 HTR2C (0.50) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL19284557 0.81 RPS6KA3 (0.51) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL30735609 0.81 RPS6KA3 (0.51) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL19284657 0.81 HTR2C (0.66) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL30735624 0.81 HTR2C (0.66) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL19297189 0.78 RPS6KA3 (0.42) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL19297102 0.78 RPS6KA3 (0.51) HTR2CSLC6A2SLC6A4HTR1ASLC6A3
SCHEMBL30735615 0.78 RPS6KA3 (0.51) HTR2CSLC6A2SLC6A4HTR1ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 SRX CARDIO, LLC (US) 2024-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 PCSK9, PCSK6, PCSK7 HTR2C 3255/4885SLC6A2 4726/4885SLC6A4 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.